HCM
CGTX icon

Hilton Capital Management’s Cognition Therapeutics CGTX Stock Holding History

Hilton Capital Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$417K Hold
548,950
– – 0.03% 128
2025
Q4 		$741K Sell
548,950
-32,200
-6% -$52.3K 0.06% 137
2025
Q3 		$785K Buy
+581,150
New +$793K 0.06% 138

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Hilton Capital Management's CGTX Position: Q1 2026 in Review

Hilton Capital Management held its Cognition Therapeutics (CGTX) position steady in Q1 2026 at 548,950 shares worth $417K. The position accounts for 0.03% of the portfolio, ranked #128.

Hilton Capital Management first reported a position in CGTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $785K in Q3 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Hilton Capital Management held 548,950 shares of Cognition Therapeutics worth $417K as of Q1 2026.
  • Hilton Capital Management left its Cognition Therapeutics share count unchanged in Q1 2026.
  • Cognition Therapeutics made up 0.03% of Hilton Capital Management's portfolio in Q1 2026, its #128 holding.
  • Hilton Capital Management first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Hilton Capital Management's Cognition Therapeutics position peaked at $785K in Q3 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Hilton Capital Management's 13F filing for Q1 2026, filed 15 May 2026.